COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

30,900 Articles (22,568 medRxiv, 8,332 bioRxiv)

Most recent first Previous |  Page 1230: Articles 12291-12300  | Next

Discovery of highly potent pancoronavirus fusion inhibitors that also effectively inhibit COVID-19 variants from the UK and South Africa
Curreli, F., Ahmed, S., Victor, S. M. B., Drelich, A., Panda, S. S., Altieri, A., Kurkin, A., Tseng, C.-T., Hillyer, C., Debnath, A.
10.1101/2021.09.03.458877 — Posted: 2021-09-03 Discussion: Onsite
Mathematical modeling and adequate environmental sampling plans are essential for the public health assessment of COVID-19 pandemics: development of a monitoring indicator for SARS-CoV-2 in wastewater
Cluzel, N., Courbariaux, M., Wang, S., Moulin, L., Wurtzer, S., Bertrand, I., Laurent, K., Monfort, P., Obepine Consortium, , Le Guyader, S., Boni, M., Mouchel, J.-M., Marechal, V., Nuel, G., Maday, Y.
10.1101/2021.09.01.21262877 — Posted: 2021-09-03
Effectiveness of COVID-19 Vaccines Against SARS-CoV-2 Infection During a Delta Variant Epidemic Surge in Multnomah County, Oregon, July 2021
Barlow, R. S., Larson, L., Jian, K.
10.1101/2021.08.30.21262446 — Posted: 2021-09-03
Immune response elicited from heterologous SARS-CoV-2 vaccination: Sinovac (CoronaVac) followed by AstraZeneca (Vaxzevria)
Yorsaeng, R., Vichaiwattana, P., Klinfueng, S., Wongsrisang, L., Sudhinaraset, N., Vongpunsawad, S., Poovorawan, Y.
10.1101/2021.09.01.21262955 — Posted: 2021-09-03
Sars-Cov-2 antibody titer 3 months post-vaccination is affected by age, gender, smoking and vitamin D.
Parthymou, A., Habeos, E. E., Habeos, G. I., Deligakis, A., Livieratos, E., Marangos, M., Chartoumpekis, D. V.
10.1101/2021.09.01.21262913 — Posted: 2021-09-03
Severe COVID-19 is characterised by inflammation and immature myeloid cells early in disease progression
Townsend, L., Dyer, A. H., Naughton, A., Imangaliyev, S., Dunne, J., Kiersey, R., Holden, D., Mooney, A., Leavy, D., Ridge, K., Sugrue, J., Aldoseri, M., Kelliher, J. H., Hennessy, M., Byrne, D. G., Browne, P., Bacon, C. L., Doyle, C., O'Riordan, R., McLaughlin, A. M., Bannan, C., Martin-Loeches, I., White, A., McLoughlin, R. M., Bergin, C., Bourke, N., O'Farrelly, C., Conlon, N., Ni Cheallaigh, C.
10.1101/2021.09.01.21262953 — Posted: 2021-09-03
Wildlife in Cameroon harbor diverse coronaviruses including many isolates closely related to human coronavirus 229E
Ntumvi, N. F., Ngum Ndze, V., Gillis, A., Le Doux Diffo, J., Tamoufe, U., Takuo, J.-M., Mouiche, M. M. M., Nwobegahay, J., LeBreton, M., Rimoin, A. W., Schneider, B. S., Monagin, C., McIver, D. J., Roy, S., Ayukekbong, J. A., Saylors, K., Joly, D. O., Wolfe, N. D., Rubin, E. M., Lange, C. E.
10.1101/2021.09.03.458874 — Posted: 2021-09-03
SARS-CoV-2 infection activates dendritic cells via cytosolic receptors rather than extracellular TLRs
van der Donk, L. E. H., Eder, J., van Hamme, J. L., Brouwer, P. J. M., Brinkkemper, M., van Nuenen, A. C., van Gils, M. J., Sanders, R. W., Kootstra, N. A., Bermejo-Jambrina, M., Geijtenbeek, T. B. H.
10.1101/2021.09.02.458667 — Posted: 2021-09-03
Characterization of SARS-CoV-2 variants B.1.617.1 (Kappa), B.1.617.2 (Delta) and B.1.618 on cell entry, host range, and sensitivity to convalescent plasma and ACE2 decoy receptor
Ren, W., Ju, X., Gong, M., Lan, J., Yu, Y., Long, Q., Zhang, Y., Zhong, J., Zhong, G., Wang, X., Huang, A., Zhang, R., Ding, Q.
10.1101/2021.09.03.458829 — Posted: 2021-09-03
Strengthening public COVID-19 response with private facilities in Kisumu, Kenya
van Duijn, S., Barsosio, H. C., Omollo, M., Milimo, E., Odero, I. A., Aroka, R., de Sanctis, T., K Oloo, A., June, M. J., Houben, N., Wilming, C., Otieno, K., Kariuki, S., Onsongo, S., Odhiambo, A., Rinke de Wit, T.
10.1101/2021.08.31.21262891 — Posted: 2021-09-03

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).